ARMP
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
Armata Pharmaceuticals, Inc. (ARMP) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B); its weakest is Momentum (D).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | B- (2.9) | B (3.2) | C- (2.1) | D (1.4) | C+ (2.6) | C (2.4) |
| 2026-11-10 | B- (2.9) | D+ (1.7) | C- (2.1) | C- (1.9) | C+ (2.6) | C (2.2) |
| 2026-11-03 | B- (2.9) | D+ (1.7) | C- (2.1) | D (1.3) | C+ (2.7) | C- (2.1) |
| 2026-10-27 | B- (2.9) | D+ (1.7) | C (2.2) | D (1.3) | C+ (2.6) | C- (2.1) |
| 2026-10-20 | B- (2.9) | D+ (1.7) | C (2.2) | D (1.4) | C+ (2.6) | C (2.2) |